Citable filing context
HCA's research view summarizes recent SEC filing context, starting with debt_offering from Jul 29, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 29, 2026 | debt_offering | HCA increased its commercial paper program capacity from $4.0 billion to $8.0 billion. |
| Jul 24, 2026 | earnings | HCA Healthcare reported second quarter 2026 revenues of $20.23 billion and net income of $1.699 billion. |
| Jul 14, 2026 | guidance_update | HCA Healthcare updated its 2026 financial guidance, lowering revenue and net income expectations due to payer mix shifts. |
| Jul 24, 2026 | Guidance: adjusted_ebitda | 15400.00 to 16100.00 |
| Jul 24, 2026 | Guidance: eps_diluted | 28.70 to 30.50 |
| Jul 24, 2026 | Guidance: net_income | 6300.00 to 6700.00 |
| Jul 28, 2026 | mda_quarterly | HCA Healthcare reported second-quarter 2026 revenues of $20.23 billion, an 8.7% increase over the prior-year period, driven by a 6.0% rise in revenue per equivalent admission and a 2.6% increase in equivalent admissions. Net income attributable to HCA reached $1.699 billion, or $7.62 per diluted share. Performance was significantly bolstered by incremental revenues from the Florida Medicaid state directed payment program, which contributed to a 23.4% increase in same-facility uninsured admissions as the company navigated the expiration of enhanced premium tax credits (EPTCs) for insurance exchange plans. Operating expenses rose, with other operating expenses increasing to 24.9% of revenue, largely due to costs associated with Medicaid supplemental payment programs and professional fees. While inpatient and outpatient surgical volumes declined by 2.3% and 4.4% respectively, emergency department visits grew by 3.5%. The company maintains a robust capital structure, with $49.72 billion in total debt and $3.09 billion available under its senior unsecured credit facility. Management expects 2026 capital expenditures to range between $5.0 billion and $5.5 billion. Despite inflationary pressures and regulatory shifts in Medicaid funding, the company continues to prioritize share repurchases, having bought back 7.909 million shares during the first half of 2026. |
| Apr 29, 2026 | mda_quarterly | First-quarter 2026 revenues increased 4.3% to $19.109 billion, with net income attributable to HCA Healthcare, Inc. totaling $1.620 billion. Growth was primarily driven by a 3.1% increase in revenue per equivalent admission, which offset declines in outpatient surgical volumes (down 2.7%) and inpatient surgical volumes (down 0.4%). These volume pressures were attributed to a significant decrease in seasonal respiratory-related activity and a January winter storm. A critical trend is the 15.6% increase in consolidated uninsured admissions following the expiration of enhanced premium tax credits and administrative reforms, raising the estimated cost of total uncompensated care to $1.252 billion. Texas and Florida remain the most vital markets, generating 51% of revenues and 73% of uninsured admissions. Operating expenses were pressured by higher cardiovascular technology costs and increased state supplemental Medicaid program spending. Cash flow from operating activities rose to $2.014 billion, supporting $1.119 billion in capital expenditures and $1.571 billion in share repurchases. Total debt reached $48.023 billion. Primary financial risks include persistent inflationary pressures on labor and supplies, as well as regulatory uncertainty surrounding Medicaid state directed payment arrangements. |
Source: SEC EDGAR filing text and events; period Jul 29, 2026; filed Jul 29, 2026.
HCA company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.